Maui Derm 2026: New Therapies for Atopic Dermatitis, Melanoma, and Psoriasis

February 9, 2026 Dr. Michael Lee – Health Editor Health

Here’s a breakdown of the key takeaways from the provided text, focusing on the updates presented at the conference:

Rocatinlimab (AMG 451/KHK4083) for Atopic Dermatitis (AD):

* Positive Trial Results: Two Phase 3 trials (NCT05398445 and NCT05651711) of rocatinlimab showed statistically significant improvements in EASI-75 and IGA scores at week 24 in patients with moderate to severe AD.
* Sustained Improvement: Clinical response continued to increase through week 24, without early plateauing.
* Impact on Quality of Life: Patients experienced meaningful gains in quality of life.
* Efficacy in Prior Treatment Failures: The drug showed efficacy even in patients who had previously not responded to other treatments.
* Safety Profile: Adverse event rates were low.
* New Therapeutic Class: Rocatinlimab represents a new therapeutic class targeting the OX40 pathway, potentially reshaping AD management.
* Limitations: Short trial duration, complex rescue protocols, and limited pediatric data were noted.

Immunotherapy for Melanoma (Nivolumab +/- Ipilimumab):

* Durable Long-Term Survival: 10-year follow-up data from a Phase 3 trial showed significant survival advantages with immunotherapy (nivolumab plus ipilimumab or nivolumab alone) compared to ipilimumab alone in unresectable stage III/IV melanoma.
* 10-Year Overall Survival Rates:
* Nivolumab + Ipilimumab: 43%
* Nivolumab alone: 37%
* Ipilimumab alone: 19%
* Benefit in BRAF-Mutant Disease: Combination therapy (nivolumab + ipilimumab) provided the greatest benefit, particularly in patients with BRAF-mutated melanoma.
* Trade-offs: Combination therapy had higher toxicity and discontinuation rates.
* 3-Year Survival Predicts Long-Term Outcome: Patients surviving 3 years had a high probability of surviving to 10 years.
* Growing Relevance of Oncodermatology: The data highlights the increasing importance of oncodermatology.

In essence, the presentation showcased promising new treatment options for both AD (rocatinlimab) and melanoma (long-term immunotherapy data), with a focus on improved efficacy, durability, and quality of life for patients.